S-1/A: Alpha Cognition Announces Employment Agreement with New VP of Finance Amidst Public Offering Plans

Alpha Cognition USA Inc. enters into an employment agreement with Henry Du as VP, Finance and Accounting, while the company prepares for a public offering.

Summary

• Alpha Cognition USA Inc. has entered into an employment agreement with Henry Du, appointing him as VP, Finance and Accounting, effective October 21, 2024, with an annual base salary of $275,000.
• Du's responsibilities include functions of his office and providing advice, information, judgment, and knowledge regarding the company's business.
• He is eligible for employee benefit and compensation programs, including a bonus compensation currently set at 40% of base salary, leave time, retirement plans, and stock plans.
• Du will be granted 800,000 stock options within 60 days of the effective date, subject to Board approval and the terms of the Equity Plan.
• The agreement includes provisions for business expenses, exclusivity of employment, and adherence to a Protective Agreement covering confidentiality and non-competition.
• Legal disputes will be resolved through binding arbitration in Texas, governed by Texas law, with certain exceptions for workers' compensation claims and actions to compel arbitration.
• The company is also in the process of a public offering, registering 4,000,000 common shares and pre-funded warrants, aiming for a Nasdaq listing under the symbol ACOG.
• The offering price is assumed at $10.00 per share, with a reverse stock split of 1-for-25 completed on November 5, 2024, to meet Nasdaq's minimum share price requirement.
• The company intends to use the net proceeds from this offering to begin its efforts toward our commercialization and launch of ZUNVEYL in AD; further research and development of our pipeline product candidates; continued commercial CMC activities (chemistry, manufacturing, and controls); and for working capital and general corporate purposes, which may include funding capital expenditures, acquisitions, and investments.

Sentiment

Score: 7

Explanation: The document is primarily factual, outlining the employment agreement and public offering plans. The sentiment is neutral to positive, reflecting the company's growth and expansion efforts.

Positives

• Appointment of experienced finance professional to key role.
• Eligibility for bonus and stock option plans provides incentive for performance.
• Company is actively pursuing a Nasdaq listing, which could increase visibility and access to capital.
• FDA approval of ZUNVEYL

Negatives

• The employment agreement includes restrictive covenants that may limit Du's future employment options.
• The company has incurred significant losses since its inception.
• The company will need substantial additional capital to meet its financial obligations and to pursue its business objectives.
• The company is subject to certain supply chain risks inherent in manufacturing our lead product, ZUNVEYL, and future products with respect to Taiwan.

Risks

• Dependence on successful commercialization of ZUNVEYL and development of other product candidates.
• Potential delays in preclinical studies and clinical trials.
• Risk of side effects or adverse events associated with therapeutic candidates.
• Competition from other pharmaceutical companies.
• Reliance on third-party suppliers for manufacturing.
• Challenges in scaling up manufacturing to commercial scale.
• Dependence on governmental authorities and health insurers for coverage and reimbursement.
• Potential for product liability lawsuits.
• Risks related to the Company being a passive foreign investment company under United States tax laws.
• The Company has outstanding warrants denominated in both Canadian and U.S. Dollars. The foreign exchange risk associated with the variable of the Canadian Dollar denominated warrant and the Companys resulting U.S. Dollar denominated functional currency could result in a significant risk of loss at the date of valuing the risk and cause the Company to incur a significant non -cash derivative liability depending on the exchange rate and share price volatility, share price, risk -free interest rate, and remaining life of the Canadian Dollar denominated warrants.

Future Outlook

The company plans to focus on commercial manufacturing and sales of ZUNVEYL, build a long-term care commercial team, and seek potential licensing partners for additional indications and new formulations.

Industry Context

The announcement comes as Alpha Cognition prepares to commercialize ZUNVEYL, a treatment for mild to moderate dementia of the Alzheimer's type, in a market with limited treatment options and high unmet need.

Comparison to Industry Standards

• The document does not provide a direct comparison to industry standards.
• However, it mentions competitors like Biogen, Eli Lilly, and Corium in the Alzheimers space, suggesting a competitive landscape.
• The document also references generic medications like donepezil, rivastigmine, galantamine, and memantine, indicating the presence of established treatments.
• The document does not provide specific details on how Alpha Cognition's results compare to these competitors in terms of efficacy, safety, or market share.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased share value through successful commercialization and Nasdaq listing.
• Employees: New employment opportunities and potential for career growth.
• Patients: Access to a new treatment option for Alzheimer's disease.
• Creditors: Potential for increased financial stability and ability to meet obligations.

Next Steps

• Complete the public offering and Nasdaq listing.
• Commercialize ZUNVEYL and build a commercial team.
• Pursue further research and development of pipeline product candidates.
• Seek strategic partnerships for ZUNVEYL distribution and development.

Key Dates

Keywords

employment agreement, VP Finance, accounting, stock options, capital raise, S-1 filing, Alpha Cognition, ZUNVEYL, Henry Du, biopharmaceutical, Alzheimers, ACOG